According to the regulatory agency, they received safety information concerning the association of sudden deaths, heart-related deaths, and strokes in children
and adults taking recommended doses of
Adderall and Adderall XR. This risk of
Adderall death seemed particularly high for individuals with structural heart abnormalities.
In response to these findings, the FDA issued an advisory warning about the possible risk of death, but allowed the drug to remain on the market.